Inhalation therapy
-
Part 1 book "A color handbook - Small animal anesthesia and pain management" includes content: Equipment for inhalant anesthesia; perioperative blood work and urine analysis; preanesthetic medication - drugs and dosages; intravenous injection techniques and intravenous anesthetic agents; inhalant anesthetic agents; anesthesia monitoring and management; fluid therapy; blood components and transfusion therapy; injectable sedative and anesthesia–analgesia combinations in dogs and cats; anesthetic considerations for specific diseases; airway management and ventilation.
243p muasambanhan05 22-01-2024 4 2 Download
-
Part 2 book "BSAVA manual of canine and feline anaesthesia and analgesia" includes content: Inhalant anaesthetic agents; neuromuscular blocking agents; haemodynamic support during the anaesthetic period; fluid therapy and blood transfusion 19. ophthalmic surgery; dental and oral surgery; cardiovascular disease; respiratory compromise; intrathoracic surgery and interventions; gastrointestinal, laparoscopic and liver procedures,... and other contents.
259p muasambanhan04 07-01-2024 5 2 Download
-
Systemic corticosteroids are considered to be the standard treatment for allergic bronchopulmonary aspergillosis (ABPA). However, there is controversy regarding use of inhaled corticosteroid (ICS) therapy for ABPA. Here we report a case of ABPA that was successfully treated with inhaled fluticasone furoate/vilanterol (FF/VI) and oral voriconazole (VRCZ).
4p viintuit 26-09-2023 3 0 Download
-
Part 2 book "Equine clinical pharmacology" includes content: Drugs acting on the urinary system; drugs acting on the reproductive system; drugs acting on the cardiovascular system, ophthalmic therapeutics; non-steroidal anti-inflammatory drugs; anesthetics, tranquillizers and opioid analgesics; inhalation therapy for the respiratory system; fluid therapy.
236p oursky05 20-09-2023 5 2 Download
-
Pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) are commonly used drugdelivering devices for patients with chronic airway diseases. Appropriate peak inhalation flow rate (PIFR) and inhaler technique is essential for effective therapy
10p vimackenziebezos 29-11-2021 10 1 Download
-
Pulmonary diseases affect health-related quality of life (HRQoL), but there are few data on patients’ adaptation to a serious illness. This study assessed resilience and its associations with HRQoL, life satisfaction, anxiety and depression in patients with pulmonary diseases receiving ambulatory oxygen therapy.
9p vijichoo2711 31-05-2021 4 1 Download
-
Chronic obstructive pulmonary disease (COPD) is an important risk factor for postoperative complications and mortality. To determine the effects of perioperative combination therapy, using a long-acting muscarinic antagonist (LAMA) and a long-acting β2 agonist (LABA), on preoperative lung function, postoperative morbidity and mortality, and long-term outcome in COPD patients.
11p vijichoo2711 31-05-2021 10 1 Download
-
This study investigated the efficacy and safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiformW), administered twice daily (b.i.d.) via a single aerosol inhaler, compared with its individual components administered separately and placebo, in patients with mild-to-moderate asthma.
15p vianthony2711 16-04-2021 12 2 Download
-
Acute asthma attacks remain a frequent cause of emergency department (ED) visits and hospital admission. Many factors encourage patients to seek asthma treatment at the emergency department.
7p vianthony2711 16-04-2021 9 1 Download
-
The purpose of this analysis was to compare health care costs and utilization among COPD patients who had long-acting beta-2 agonist (LABA) OR long-acting muscarinic antagonist (LAMA); LABA AND LAMA; or LABA, LAMA, AND inhaled corticosteroid (ICS) prescription claims.
9p vianthony2711 16-04-2021 8 1 Download
-
An increased incidence of pneumonia in patients with chronic obstructive pulmonary disease (COPD) under inhaled corticosteroid (ICS) therapy was noticed in previous studies. We performed a prospective study to elucidate the risk factors for the development of pneumonia in this group of patients.
7p vianthony2711 16-04-2021 12 2 Download
-
Despite the availability of effective therapies, asthma remains a source of significant morbidity and use of health care resources. The central research question of the ACCURATE trial is whether maximal doses of (combination) therapy should be used for long periods in an attempt to achieve complete control of all features of asthma.
11p vianthony2711 16-04-2021 12 2 Download
-
The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinations of these substances.
9p vianthony2711 16-04-2021 9 1 Download
-
The lectin-like domain of TNF-α can be mimicked by synthetic TIP peptides and represents an innovative pharmacologic option to treat edematous respiratory failure. TIP inhalation was shown to reduce pulmonary edema and improve gas exchange.
11p vimontana2711 05-04-2021 9 2 Download
-
Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD).
9p vimontana2711 05-04-2021 17 2 Download
-
Effectiveness of Montelukast on asthma control in infants: Methodology of a French claims data study
This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months) compared to inhaled corticosteroids (ICS), based on real-world data.
7p vimontana2711 05-04-2021 11 2 Download
-
Although asthma morbidity can be prevented through long-term controller medication, most patients with persistent asthma do not take their daily inhaled corticosteroid. The objective of this study was to gather patients’ insights into barriers and facilitators to taking long-term daily inhaled corticosteroids as basis for future knowledge translation interventions.
11p vimontana2711 05-04-2021 10 1 Download
-
Novel therapies need to be evaluated in normal clinical practice to allow a true representation of the treatment effectiveness in real-world settings. Methods/design: The Salford Lung Study is a pragmatic randomised controlled trial in adult asthma, evaluating the clinical effectiveness and safety of once-daily fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg in a novel dry-powder inhaler, versus existing asthma maintenance therapy.
5p vimontana2711 05-04-2021 10 1 Download
-
COPD is a treatable disease with increasing prevalence worldwide. Treatment aims to stop disease progression, to improve quality of life, and to reduce exacerbations. We aimed to evaluate the association of the stage of COPD on adherence to inhaled therapy and the relationship between adherence and COPD exacerbations.
6p vimontana2711 05-04-2021 12 2 Download
-
Aerosol delivery through a nasal high flow (NHF) system is attractive for clinicians as it allows for simultaneous administration of oxygen and inhalable drugs. However, delivering a fine particle fraction (FPF, particle wt. fraction < 5.0 μm) of drugs into the lungs has been very challenging, with highest value of only 8%.
11p vimontana2711 05-04-2021 9 2 Download